IRIDEX Net Income/Loss 2010-2025 | IRIX
IRIDEX net income/loss from 2010 to 2025. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
IRIDEX Annual Net Income/Loss
(Millions of US $) |
| 2024 |
$-9 |
| 2023 |
$-10 |
| 2022 |
$-8 |
| 2021 |
$-5 |
| 2020 |
$-6 |
| 2019 |
$-9 |
| 2018 |
$-13 |
| 2017 |
$-13 |
| 2016 |
$-12 |
| 2015 |
$0 |
| 2014 |
$10 |
| 2013 |
$2 |
| 2012 |
$1 |
| 2011 |
$3 |
| 2010 |
$3 |
| 2009 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Laser Systems and Components |
$0.018B |
$0.049B |
|
IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market.
|
